bydrug.pharmcube.com
2025 ESMO...
Dec 8, 2025 · 此项RATIONALE-304研究的事后分析，填补了这一临床空白——数据提示，此类患者一线进展后继续替雷利珠单抗治疗可带来持续的生存获益且安全性可控，为这类患者的后续治疗方案制定提供了重要参考。 临床实践的核心需求在于识别TBP获益人群。
rationale304 研究
Searching…
Web results
www.163.com
2024 ESMO ASIA |...
Dec 6, 2024 · 研究介绍 RATIONALE-304研究是一项III期、多中心、随机对照研究，旨在评估替雷利珠单抗联合铂类+培美曲塞对比铂类+培美曲塞一线治疗晚期非鳞NSCLC的疗效和安全性（图1）。
pubmed.ncbi.nlm.nih.gov
Tislelizumab Plus Chemotherapy as First-Line Treatment for ...
Addition of tislelizumab to chemotherapy resulted in significantly prolonged PFS, higher response rates, and longer response duration compared with chemotherapy alone, identifying a new potential option for first-line...
www.beonemedinfo.com
RATIONALE 304: Tislelizumab Plus Chemotherapy Versus ...
RATIONALE 304 is a Phase 3, open-label, multicenter, randomized study to evaluate the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum a...
www.sohu.com
【2022 ESMO...
Dec 6, 2022 · RATIONALE-304 研究中 PD-L1 表达水平更接近真实世界数据，疗效数据更具代表性 [11-16]。 RATIONALE-304研究是一项III期、多中心、随机、开放研究，旨在评估替雷利珠单抗联合培美曲塞和铂类对比培美曲塞和铂类一线治疗晚期非鳞状NSCLC的疗效和安全性。
xueqiu.com
$康方生物 (09926)$ “RATIONALE-304和RATIONALE-307研究分别是替雷利珠单抗联合化疗一线治...
Apr 28, 2025 · $康方生物 (09926)$ “RATIONALE-304和RATIONALE-307研究分别是替雷利珠单抗联合化疗一线治疗非鳞NSCLC和鳞状NSCLC的III期研究。首次公布结果时PFS均显著获益并获批适应症，但在2022年ESMO IO大会上公布的OS结果显示，替雷利珠单抗联合化疗一线治疗非鳞癌mOS 为21.6个月（对照组20.1个月），相较对...
www.esmoopen.com
Tislelizumab plus chemotherapy as first-line treatment of ...
Sep 25, 2024 · The purpose of this study was to report an updated, final analysis with longer follow-up for the open-label phase III RATIONALE-304 study of first-line tislelizumab plus chemotherapy versus chemotherapy...
www.annalsofoncology.org
632P RATIONALE-304 long-term outcomes: First-line ...
First-line TIS + chemo improved PFS vs chemo in patients (pts) with metastatic NSQ NSCLC without sensitizing EGFR/ALK alterations in the RATIONALE-304 study (NCT03663205). Here, we reported updated results with around...
www.beonemedinfo.com
ligand 1 (PD-L1) 3 RATIONALE-304 - beonemedinfo.com
Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥...
www.medsci.cn
AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）...
Apr 10, 2022 · AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究 2022-04-10 网络 网络